Punstoppable
A list of puns related to "Cemi"
Are the share holders happy with the way the board has been running this company? I am not, they are still having hiring issues. Poor reviews from employees flood the hiring boards. Big complaint is management and high turn over rate. They gave a huge severance out of 400k reported last quarter. I think they are over paying their top people and need to hire people that will turn this around. Cemi has been terrible with communication to their share holders or showing any push to become more efficient. I think we need to discuss getting a great enough percentage of share holders together and have changes made, they seem to be taking advantage of us and we are not benefitting from their direction. Thoughts?
$CEMI Fun fact volume hasn't been this low since mid July. Guess what happened on the 21 of July? jumped to $6.85.
Potential Catalysts:
Fundamentals:
If you are jumping in here, note they raised $38.8 million US in July and received $32 million in purchase orders currently being delivered. Q3 YOY revenue up 17%. Total assets at $84million. Also hired a veteran CFO with experience in healthcare (Siemens). Current valuation is less than cash on hand.
Headwinds: Supply chain issues which they have already begun rectifying with incentives to jump on board with Chembio, including signing bonuses (were hiring over 100 new personnel). chembio.com/investors/press.... Are in the process of resubmitting information for EUA approval. Share price has been knocked back as a result. Very undervalued. Expecting solid uptrend with any PR as they continue to fill large Brazilian order.
Technicals:
MACD line crossing the signal line on the daily and 30 min chart with possibly curling on the 1hr. Oversold from late December to early Jan. Order flow has strong inflow.
1min and 5 min support (S1) at $1.12. Resistance (R1) at $1.20. Position Cost Distribution at a whopping $5.07 (this is the price the average investors holds the stock at). 90% of cost Concentration sits between $3.08 and $6.48.
**not a financial advisor this is not investment advice
Another COVID play. Micro cap. Easy!
$CEMI. Best opportunity in the market short term.
Awaiting approvals on three Covid tests and a C.L.I.A for its 2 in 1 HIV-SYPHILIS test.
The news will double/triple the share price.
Buy a few shares today before the approvals are announced.
Potential takeover target. Possible suitors are $JNJ, $DGX, $AZN and $TAK.
Takeover at $10+.
The company has worked with each of them on developing testing.
Company is awaiting approval on two Covid tests and for a C.L.I.A. for its dual HIV-SYPHILIS test.
The dual Covid test which detects both the flu and Covid has already been approved in South Africa and Brazil and is awaiting E.U.A. approval.
The "quick response" 15 minute Covid test is awaiting both F.D.A. and E.U.A. approval which could be announced at any time.
Any of these approvals have the potential to double or triple the share price.
Consider buying a few shares today. It's substantially undervalued.
The shorts have once again oversold it. The company has approval pending on two Covid tests and a C.L.I.A for its dual HIV-SYPHILIS test.
In regards to the test for which the F.D.A. requested additional data I expect the company working with BARDA will meet the requested data requirements and the test will be approved.
Company is definitely a potential takeover target at such a low valuation. $8?
Buy a few shares before the move higher.
CEMI, or Chembio Diagnosis, is a developer of biotech products.
Today, they received authorization in South Africa for their DPP SARS-CoV-2 Antigen test to be marketed and distributed. By healthcare providers in the country
This is a COVID antigen test that can return results in 20 minutes.
https://pulse2.com/chembio-diagnostics-nasdaq-cemi-stock-why-the-price-jumped-today/
>The stock price of Chembio Diagnostics Inc (NASDAQ: CEMI) – a leading point-of-care diagnostics company focused on infectious diseases – increased by over 15% pre-market today. Investors are responding positively to Chembio Diagnostics announcing receipt on November 26, 2021, of South Africa Health Products Regulatory Authority (SAHPRA) approval for the DPP SARS-CoV-2 Antigen test, authorizing marketing and distribution of the test for use at the point of care by professional healthcare providers.
>
>The DPP SARS-CoV-2 Antigen test has been designed to detect SARS-CoV-2 antigens in only 20 minutes. And the DPP SARS-CoV-2 Antigen test uses a minimally invasive nasal swab and is designed to be read visually or with a DPP Micro Reader 2 optical analyzer.
>
>Both the DPP SARS-CoV-2 Antigen test and the IgM/IgG Antibody test are authorized for import and distribution in South Africa by Chembio’s distributor Patient Focus Africa, pursuant to licenses issued by SAHPRA. And PFA is a World Health Organization accredited company for near-patient testing, wellness, and professional point of care testing. PFA is partially owned by Discovery Health, the largest private healthcare Insurance provider in South Africa, and services both the public and private healthcare markets in the country.
With the Omicron variant spreading throughout South Africa, this may be a good opportunity for growth in the country, where Chembio has already administered.
In September, Chembio submitted this Covid test to the FDA for an emergency use filing.
https://www.benzinga.com/fda-biotech#historical
https://preview.redd.it/7yulsixekk281.png?width=2250&format=png&auto=webp&s=1ef31c0592c2f6a27d9366183040db98af2d0c0e
[https://www.benzinga.com/pressreleases/21/11/g24133753/chembio-diagnostics-submits-eua-application-for-new-dpp-sars-cov-2-antigen-test](https://www.benzinga.com/pressreleases/21/11/g24133753/chembio-diagnostics-submits-eu
... keep reading on reddit ➡LinkedIn: https://www.linkedin.com/in/larry-steenvoorden-cpa-mba/
Source: https://quantisnow.com/insight/2218347?s=s
New CFO worked for Siemens Healthineers. A multi billion dollar healthcare company: https://www.boerse-frankfurt.de/equity/siemens-healthineers-ag.
Why would Biden administration do something like this instead of giving the contract to the already US based companies like CEMI ? this is our tax money !!!
It's only a matter of time before either an F.D.A. or E.U.A. approval is announced and doubles the share price.
It has happened before and it will happen again.
Current share price is less than cash on hand.
Shorts need millions of shares.
I'm adding shares everyday.
GLTA!!!
Who’s grabbing thousands of shares before we see triple digits???
Looks as though a few more financial institutions bought in to Chembio last week. Good to see the continued interest. Hopefully this continues this week.
https://preview.redd.it/7zz37t5o09u71.png?width=1111&format=png&auto=webp&s=8706768870a2faaf7ae4695aa55b6770128cffbd
Source: https://fintel.io/so/us/cemi
***This is not financial advice, Not an investment advisor
$CEMI. Chembio Diagnostics. Best opportunity in the market short term.
Awaiting approvals on three Covid tests and a C.L.I.A for its 2 in 1 HIV-SYPHILIS test.
The news will double/triple the share price.
Buy a few shares today before the approvals are announced.
Chembio Diagnostics Receives SAHPRA Approval for DPP SARS-CoV-2 Antigen Test
HAUPPAUGE, N.Y., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced receipt on November 26, 2021, of South Africa Health Products Regulatory Authority (SAHPRA) approval for the DPP SARS-CoV-2 Antigen test, authorizing marketing and distribution of the test for use at the point-of-care by professional healthcare providers.
“We are pleased that independent evaluation of the DPP SARS-CoV-2 Antigen test again demonstrated strong sensitivity and specificity performance. This is another validation of the DPP technology that expands the regulatory approvals received by our COVID testing portfolio,” said Richard Eberly, Chembio’s President and Chief Executive Officer. “South Africa represents a large testing market opportunity. We are excited to provide our distributor, Patient Focus Africa (PFA), with another testing solution in addition to our DPP SARS-CoV-2 IgM/IgG Antibody test, to help manage the evolving needs of the pandemic in South Africa.”
The DPP SARS-CoV-2 Antigen test has been designed to detect SARS-CoV-2 antigens in only 20 minutes. The DPP SARS-CoV-2 Antigen test uses a minimally invasive nasal swab and is designed to be read visually or with a DPP Micro Reader 2 optical analyzer. Both the DPP SARS-CoV-2 Antigen test and the IgM/IgG Antibody test are authorized for import and distribution in South Africa by Chembio’s distributor, Patient Focus Africa, pursuant to licenses issued by SAHPRA. PFA is a World Health Organization accredited company for near patient testing, wellness, and professional point of care testing. PFA is partially owned by Discovery Health, the largest private healthcare Insurance provider in South Africa, and services both the public and private healthcare markets in the country.
**“We have 22 years’ experience of using quality point of care and rapid tests in the Southern African market. We have conducted millions of tests over this period of time. Let me state unequivocally: the Chembio DPP platform/test is in a league of its own. The quality control built into the strip, the ease of collecting quality samples, and the receipt of results that you can trust time after time – this is truly lifesaving,” said Jacques du Toit, Founder and Manager Director of Patient Focus Africa. “These sentiments are expressed and sha
... keep reading on reddit ➡Please note that this site uses cookies to personalise content and adverts, to provide social media features, and to analyse web traffic. Click here for more information.
